ArticleBioengineering (Basel, Switzerland)2024
Cancerous and Non-Cancerous MRI Classification Using Dual DCNN Approach.
Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Multi-Sequence Guided Generation of Contrast-Enhanced Magnetic Resonance Imaging Using Diffusion Models.Bioengineering (Basel, Switzerland) · 2026Article
- A Review of Data Engineering in United States Healthcare Infrastructure.Healthcare (Basel, Switzerland) · 2026Review
- Explainable Deep Ensemble Meta-Learning Framework for Brain Tumor Classification Using MRI Images.Cancers · 2025Article
- Artificial Intelligence in Public Health: Bridging Today's Trends with Tomorrow's Possibilities.Bioengineering (Basel, Switzerland) · 2025Article
- Convolutional Neural Network Incorporating Multiple Attention Mechanisms for MRI Classification of Lumbar Spinal Stenosis.Bioengineering (Basel, Switzerland) · 2024Article
- Anterior Cruciate Ligament Tear Detection Based on T-Distribution Slice Attention Framework with Penalty Weight Loss Optimisation.Bioengineering (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain cancer is a life-threatening disease requiring close attention. Early and accurate diagnosis using non-invasive medical imaging is critical for successful treatment and patient survival. However, manual diagnosis by radiologist experts is time-consuming and has limitations in processing large datasets efficiently. Therefore, efficient systems capable of analyzing vast amounts of medical data for early tumor detection are urgently needed. Deep learning (DL) with deep convolutional neural networks (DCNNs) emerges as a promising tool for understanding diseases like brain cancer through medical imaging modalities, especially MRI, which provides detailed soft tissue contrast for visualizing tumors and organs. DL techniques have become more and more popular in current research on brain tumor detection. Unlike traditional machine learning methods requiring manual feature extraction, DL models are adept at handling complex data like MRIs and excel in classification tasks, making them well-suited for medical image analysis applications. This study presents a novel Dual DCNN model that can accurately classify cancerous and non-cancerous MRI samples. Our Dual DCNN model uses two well-performed DL models, i.e., inceptionV3 and denseNet121. Features are extracted from these models by appending a global max pooling layer. The extracted features are then utilized to train the model with the addition of five fully connected layers and finally accurately classify MRI samples as cancerous or non-cancerous. The fully connected layers are retrained to learn the extracted features for better accuracy. The technique achieves 99%, 99%, 98%, and 99% of accuracy, precision, recall, and f1-scores, respectively. Furthermore, this study compares the Dual DCNN's performance against various well-known DL models, including DenseNet121, InceptionV3, ResNet architectures, EfficientNetB2, SqueezeNet, VGG16, AlexNet, and LeNet-5, with different learning rates. This study indicates that our proposed approach outperforms these established models in terms of performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.